Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IN-VIVO DETECTION OF MALIGNANT THYMIC MASSES BY INDIUM-111-DTPA-D-PHE(1)-OCTREOTIDE SCINTIGRAPHY
Autore:
LASTORIA S; VERGARA E; PALMIERI G; ACAMPA W; VARRELLA P; CARACO C; BIANCO RA; MUTO P; SALVATORE M;
Indirizzi:
VIA MODIGLIANI 66-68 I-81031 AVERSA CE ITALY NCI,DEPT NUCL MED,FONDAZ G PASCALE NAPLES ITALY CNR,CTR NUCL MED NAPLES ITALY UNIV NAPLES FEDERICO II,DEPT MOL & CLIN ONCOL & ENDOCRINOL NAPLES ITALY
Titolo Testata:
The Journal of nuclear medicine
fascicolo: 4, volume: 39, anno: 1998,
pagine: 634 - 639
SICI:
0161-5505(1998)39:4<634:IDOMTM>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
SOMATOSTATIN RECEPTOR SCINTIGRAPHY; MYASTHENIA-GRAVIS; HUMAN THYMOMAS; BREAST-CANCER; TUMORS; LOCALIZATION; INDIUM-111-PENTETREOTIDE; PROLIFERATION; OCTREOTIDE; DIAGNOSIS;
Keywords:
THYMOMA; INDIUM-111-OCTREOTIDE; SOMATOSTATIN RECEPTORS; MYASTHENIA GRAVIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
38
Recensione:
Indirizzi per estratti:
Citazione:
S. Lastoria et al., "IN-VIVO DETECTION OF MALIGNANT THYMIC MASSES BY INDIUM-111-DTPA-D-PHE(1)-OCTREOTIDE SCINTIGRAPHY", The Journal of nuclear medicine, 39(4), 1998, pp. 634-639

Abstract

Many tumors with neuroendocrine characteristics express high amounts of somatostatin receptors that enable in vivo imaging with [(111) In-DTPA-D-Phe(1)]-octreotide. In this study, we have analyzed the feasibility in detecting and characterizing thymic masses by somatostatin receptor scintigraphy (SRS), Methods: Eighteen patients (13 women, 5 men, ages 18-78 yr; mean +/- s.d. = 42.1 +/- 17.6 yr) were enrolled in thisstudy, Eleven patients were studied during diagnosis and seven duringroutine follow-up, In seven patients, myasthenia gravis was the presenting symptom. SRS was performed within 4 wk after CT and/or MRI, Planar and tomographic images were acquired within 24 hr after the injection of approximately 111 MBq of [(111) In-DTPA-D-Phe(1)]-octreotide. The scintigraphic results were categorized according to the histologic findings, Results: Histology diagnosed 10 mixed epithelial/lymphoid thymomas (8 with prevalent epithelial component), 2 thymic carcinomas, 1 thymic carcinoid, 1 lymphangioma and 4 thymic hyperplasias. Two thymoma were Stage I, 3 were Stage II, 2 were Stage III and 5 were Stage IV,as was the thymic carcinoid. Indium-111-DTPA-D-Phe(1)-octreotide concentrated in primary and/or metastatic sites of thymic tumors, thereby enabling successful external gamma imaging of sites greater than 1.5 cm in size, Tumor-to-lung (T/L) ratios were as high as 7.6-fold (range 1.7-7.6). Untreated thymomas showed higher T/L (4.34 +/- 1.57) than treated ones (2.68 +/- 1.18). No uptake was detectable in the four patients with benign thymic hyperplasia and the patient with the lymphangioma. Conclusion: Indium-111-DTPA-D-Phe(1)-octreotide is avidly concentrated within thymic tumors, but it is not concentrated by thymic hyperplasia, which allows differential diagnosis. Thus, in patients with myasthenia gravis, SRS may have a role in characterizing thymic masses, thereby overcoming the limits of cross-sectional imaging modalities.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 19:50:32